Oncology

Breast cancer research
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #Clinical trials #Oncology

The latest advances in breast cancer therapy

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including… Read More

#Cancer Research #News #Trending News

Colorectal cancer
#Bowel cancer #Cancer research #Cidara #ESMO #Immuno-oncology #Oncology #Preclinical development

Drug-Fc conjugates exhibit robust anti-tumour activity

A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We are thrilled to be presenting promising preclinical data on our novel multi-specific… Read More

#Cancer Research #News

CAR-T therapy
#Blood cancer #CAR-T #Haematology #Kite Pharma #Oncology #Real world data

Real-world evidence supports use of CAR-T therapies in blood cancers

Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7% in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). Axicabtagene ciloleucel was also associated with less than 5% grade ≥3 cytokine… Read More

#Cancer Research #News #Trending News

Colon cancer
#Bowel cancer #Cancer research #Chemotherapy-resistance #Oncology #University College London #Yale University

New discovery could make bowel cancer treatment more effective

Chemotherapy becomes less effective because healthy cells push cancer cells to grow more slowly, according to the findings of two studies from University College London (UCL) and Yale University. Bowel cancer kills over 900,000 people a year and is the second highest cause of cancer mortality… Read More

#Cancer Research #Editor's Choice #News

Natural killer cells
#Bispecific Antibodies #Cell therapy #Collaboration #NAYA Biosciences #Oncology #ONK Therapeutics

Partners explore NK cell therapy and bispecific antibodies combo

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell… Read More

#Business & Investment #Cancer Research #News

Acute lymphoblastic leukemia
#Blood cancer #Eli Lilly #FDA #Leukaemia #Oncology

FDA approves second indication for Lilly’s BTK inhibitor Jaypirca

Eli Lilly’s Jaypirca (pirtobrutinib) has been approved in the US for lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). It has been granted approval by the Food and Drug Administration (FDA) to treat patients who have received at least two lines of therapy, including a Bruton’s tyrosine… Read More

#News #Regulatory

Ovarian cancer cells
#Cancer research #Cancer vaccine #CureLab Oncology #DNA #Oncology #Women's health

DNA therapy effective against chemo-resistant ovarian cancer

A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer. The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a… Read More

#Cancer Research #Editor's Choice #News

FDA approval
#FDA #Oncology #Regulatory #SpringWorks Therapeutics #Tumours

FDA approves first therapy for rare non-cancerous tumours

SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has become the first drug to be approved for desmoid tumours in the US, following the go-ahead from the US Food and Drug Administration (FDA). Desmoid tumours are non-cancerous but can be locally aggressive. Although surgical removal has historically been the treatment… Read More

#News #Regulatory

Jennifer Doudna
#Brain cancer #Cancer research #CRISPR #CRISPR Therapeutics #Gladstone Institutes #Oncology

CRISPR ‘cancer shredding’ technique destroys brain tumours

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. Using a technique they’ve dubbed “cancer shredding,” the researchers at Gladstone Institutes programmed CRISPR to zero-in on repeating DNA sequences present only… Read More

#Cancer Research #Editor's Choice #News

FDA headquarters
#Adverse event #Blood cancer #CAR-T #Cell therapy #FDA #Immunotherapy #Oncology

FDA investigates safety of CAR-T cell immunotherapies

The Food and Drug Administration (FDA) said it will investigate the safety of BCMA- or CD19-directed autologous CAR-T cell immunotherapies, following reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in these patients. The reports were received from clinical trials and postmarketing adverse event… Read More

#News #Regulatory #Trending News

Non-small cell lung cancer
#Apollomics #Avistone Biotechnology #China #Non-small cell lung cancer (NSCLC) #Oncology

c-Met inhibitor approved in China for lung cancer

The Chinese National Medical Products Administration (NMPA) has granted conditional approval to Apollomics’ partner Avistone Biotechnology to commercialise vebreltinib (APL-101) in China for MET exon 14 skipping non-small cell lung cancer (NSCLC). “The NMPA approval of vebreltinib is an important milestone toward providing a new treatment… Read More

#News #Regulatory

Business financing
#Cancer immunotherapy #Cancer vaccine #Financing #Immunotherapy #Nouscom #Oncology

Cancer immunotherapy company raises €67.5 million

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalised viral vector-based cancer vaccines, has raised €67.5 million in an oversubscribed Series C financing round. The proceeds will enable Nouscom to advance its pipeline and complete Phase II clinical trials with its cancer vaccine NOUS-209. Read More

#Business & Investment #News

Multiple myeloma
#Arcellx #CAR-T #Cell therapy #Clinical trial #Haematology #Myeloma #Oncology #Phase I trial

CART-ddBCMA trial shows durable response in myeloma patients

Arcellx has revealed encouraging interim data from its Phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The company plans to present new data with a median follow-up of 26.5 months at the 65th American Society of Hematology (ASH) Annual Meeting and… Read More

#Cancer Research #News

CAR-T therapy
#Cancer research #CAR-T #Cell therapy #EMA #Kite Pharma #Oncology #Phase III trial

CAR-T therapy Yescarta reduces risk of death by more than 27%

New trial evidence has shown that Kite’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel: axi-cel) reduces the risk of death by 27.4% in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), corresponding to a 38% improvement in overall survival (OS). It is the only treatment… Read More

#Cancer Research #News #Regulatory

Cancer research
#Cancer research #DDW Turning Science into Business Summit #Immunotherapy #Oncology #Webinar

Just two days till DDW’s Cancer Research Summit

Don’t forget to register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading international figures. The event, which will be sponsored by Taconic Biosciences, will take place online on 16 November at 7AM… Read More

#Cancer Research #Editor's Choice #News

#Cancer #Cancer research #DDW Turning Science into Business Summit #Drug discovery #Immunotherapy #Oncology

New DDW Highlights episode: 13 November 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With the first DDW Turning Science into Business Summit taking… Read More

#News